Adjuvant therapy in resected pancreatic cancer: A systematic review of literature with meta-analysis of randomized clinical trials. A phase II trial of gemcitabine in combination with oxaliplatin and ...

Bleeding events and eligibility requirements in studies evaluating an antiangiogenic agent in hepatocellular carcinoma (HCC). Background: Few effective treatments exist for unresectable hepatic ...

Please provide your email address to receive an email when new articles are posted on . There are four scenarios in which patients with HCC and extrahepatic disease (EHD) should be considered for ...

A minimally invasive treatment that delivers cancer-killing radiation directly to tumors shows promise in treating breast cancer that has spread to the liver when no other treatment options remain.

March 29, 2012 (Orlando, Florida) — Results of the largest study to date assessing the efficacy of radioembolization with yttrium-90 microspheres in the treatment of unresectable hepatic tumors have ...

Survival of patients treated with SIR-Spheres more than double that of patients who received best supportive care, benefit rivals that found with new biological agents, authors note The results of a ...

BARCELONA, Spain — Treating locally advanced hepatocellular carcinoma (HCC) with radioembolization results in better tumor responses and quality of life than the current standard of care, sorafenib ...

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed ...

Radioembolization is a generally painless procedure for liver cancer that directly targets the blood supply to the tumor site. Approximately 70% to 95% of patients will experience improvements in ...

Transarterial yttrium-90 radioembolization (TARE) combined with second-line chemotherapy improved progression-free survival (PFS) in patients with unresectable colorectal cancer liver metastases, ...

Background. A 58-year-old white man who was being followed by his hepatologist for nonalcoholic steatohepatitis-related liver cirrhosis and portal hypertension and who had been found to have a ...

WESTMINSTER, Colo., April 23, 2014 /PRNewswire/ -- Surefire Medical, Inc. announced that a symposium focused on the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial will be held ...